Skip to main content

News

High Dose Chloroquine Harmful in Severe COVID-19

JAMA Open Network reports an interim analysis of the Brazilian CloroCovid-19 trial showing thta higher doses of chloroquine (CQ) in the treatment of severe COVID-19 was associated with QTc interval prolongation and increased mortality.

RheumNow Podcast – In Times of Trouble (4.24.20)

Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com

How Has COVID-19 Affected You?

I need your HELP and INPUT.

Potential Role of B Cells in COVID

A pre-proof letter to the editor in the Journal of Allergy and Clinical Immunology presents a series of patients with immunoglobulin deficiency disorders and how they differentially responded when infected with the coronavirus. They identified seven Primary Antibody Deficiencies patients with COVID-19 infection; five affected with Common Variable Immune Deficiencies and two affected with Agammaglobulinemia, one with X-linked Agammaglobulinemia and one with Autosomal Recessive Agammaglobulinemia.

FDA Consumer Warnings on Cannabis and CBD

The FDA issued a new consumer update on what you need to know about Cannabis or Cannabis-derived Compounds, Including CBD. This is part of the FDA effort to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds, particularly CBD.

NIH Consensus Guidelines for the Treatment of COVID-19

A National Institutes of Health (NIH) expert panel has developed consensus treatment guidelines for the management of coronavirus (COVID-19). To date no drug has been proven to be safe and effective for treating COVID-19. Moreover, they found no evidence to recommended the use of hydroxychloroquine for prophylaxis or treatment of COVID-19 outside of a current clinical trial.

TNR Grand Rounds - Moving Forward with Telemedicine

Dr. Alvin Wells gives a primer on Telerheumatology and Telemedicine in the era of COVID-19. This 1 hour Grand Rounds Presentation includes a 30 minute lecture, followed by stimulating 30 minutes of Q&A with a rheumatology attendee audience.

COVID-19 and the Slippery Road of Cytokine Storms

Early reports on the COVID-19 pandemic allude to a cytokine storm or hyper-inflammation, especially in patients who succumbed to the illness.

Lower Risk of Diabetes with Abatacept

 Patients with rheumatoid arthritis (RA) treated with abatacept (Orencia) had a lower risk of developing diabetes mellitus compared with those receiving certain tumor necrosis factor (TNF) inhibitors, a large cohort study suggested.

A Role for Netosis in COVID-19 Infection?

Journal of Experimental Medicine has published a paper from a consortium of researchers at Cold Spring Harbor Laboratory, the Feinstein Institutes for Medical Research, and the Research Institute of the McGill University Health Centre (RI-MUHC) on the potential of neutrophil extracellula

Tuesday Nite Rheumatology Grand Rounds - Febrile Disorders

Dr. Jack Cush reviews the appproach to evaluating fever in adults suspected of having a rheumatic disease, Stills disease or autoinflammatory conditions.

RheumNow Podcast – Drive Them Crazy (4.17.20)

Dr. Jack Cush reviews the news, journal articles and new ACR COVID-19 guidelines from the past week on RheumNow.com.
×